関連する実験動画
Updated: Feb 27, 2026

07:02
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
7.8K
Myc阻害をがん治療法としてモデル化
Laura Soucek1, Jonathan Whitfield, Carla P Martins
1Department of Pathology and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94143-0875, USA.
Nature
|August 22, 2008
まとめ
細胞成長の重要な要因であるMycをターゲットにすることで,マウスの肺腫瘍を効果的に縮小させることができます. このアプローチは,正常な組織で管理可能な副作用を持つがん治療の有望性を示しています.
科学分野:
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
- 遺伝学 遺伝学とは
背景:
- Mycは細胞の成長と増殖に不可欠な転写因子です.
- 癌におけるマイクの役割は,それを潜在的な治療目標にしています.
- Myc阻害には,潜在的な副作用と薬剤設計による課題があります.
研究 の 目的:
- 系統的なMyc阻害の治療効果と副作用を遺伝子モデル化するために.
- Ras誘発性肺腺癌の維持におけるMycの役割を研究するために,in vivo.
- 正常組織におけるMyc阻害の耐受性および可逆性を評価する.
主な方法:
- Ras誘発肺腺癌の臨床前マウスモデルを使用した.
- 主要干渉するMyc変異体の可逆的,全身的な発現を採用した.
- 腫瘍の回帰をモニタリングし,正常な再生組織に与える影響.
主要な成果:
- システミックなMyc阻害は,初期の肺腫瘍と既成の肺腫瘍の両方の急速な回帰をもたらしました.
- Ras駆動腫瘍が内生的なMyc機能に予期せぬ依存性を示した.
- 正常な再生組織に深刻だがよく耐える,迅速に回復する効果が観察された.
結論:
- Myc阻害は,Ras依存がんを標的とした実行可能で効果的な戦略です.
- ターゲティングMycは,管理可能な副作用のある腫瘍特有の治療アプローチを提供します.
- Myc阻害は,一般的な腫瘍原性の経路をターゲットにすることで,がん治療の有望な道を示しています.
関連する概念動画
Mouse Models of Cancer Study
6.6K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
6.6K
Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Mitogens and the Cell Cycle
8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Abnormal Proliferation
5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K

